Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began
Executive Summary
New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.
You may also be interested in...
US FDA's On-Time Review Decision Rates Slip During The Pandemic, Especially For Biosimilars
Likelihood of an on-time decision on a biosimilar application dropped significantly during the first nine months of the pandemic and declined a bit for new and generic drug applications. FDA says BsUFA review performance is function of program's small sample size.
Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Generic Drug Approvals Still Winning The Pandemic At US FDA
Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.